Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-26
2006-12-26
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S233200, C514S254080, C514S323000, C514S339000, C514S364000, C514S365000, C514S394000, C514S397000, C514S410000, C514S414000, C514S422000, C540S576000, C544S142000, C544S372000, C546S200000, C546S276700, C548S131000, C548S132000, C548S181000, C548S305100, C548S312100, C548S420000, C548S455000, C548S518000
Reexamination Certificate
active
07153848
ABSTRACT:
Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.
REFERENCES:
patent: 2005/0119318 (2005-06-01), Hudyma et al.
patent: WO 01/47883 (2001-07-01), None
patent: WO 02/04425 (2002-01-01), None
patent: WO 03/007945 (2003-01-01), None
patent: WO 03/010140 (2003-02-01), None
patent: WO 03/010141 (2003-02-01), None
patent: WO 2004/064925 (2004-08-01), None
patent: WO 2004/065367 (2004-08-01), None
patent: WO 2004/087714 (2004-10-01), None
patent: WO 2004/099241 (2004-11-01), None
patent: WO 2005/012288 (2005-02-01), None
patent: WO 2005/014543 (2005-02-01), None
patent: WO 2005/034941 (2005-04-01), None
patent: WO 2005/080388 (2005-09-01), None
patent: WO 2005/080399 (2005-09-01), None
Rivara et al. “Three-Dimensional Quantitative Structure-Activity Relationship Studies on Selected MT1 and MT2 Melatonin Receptor Ligands: Requirements for Subtype Selectivity and Intrinsic Activity Modulation” J. Med. Chem. 2003, vol. 46, pp. 1429-1439.
S. Harper, et al, “Potent Inhibitors of Subgenomic Hepatitis C Virus RNA Replication Through Optimization of Indole-N-Acetamide Allosteric Inhibitors of the Viral NS5B Polymerase,” J. Med. Chem., 48(14), pp. 4547-4557, 2005.
S. Harper, et al, “Development and Preliminary Optimization of Indole-N-Acetamide Inhibitors of Hepatitis C Virus NS5B Polymerase,” J. Med. Chem., 48(5), pp. 1314-1317, 2005.
Grinev, A.N., et al, “Synthesis and Biological Activity of Aminoacetyl and Aminoethyl Derivatives of Indole [1,2-c] Quinazoline,” Khimiko-Farmatsevticheskii Zhurnal, Vses. Nauchno-Issled. Khim-Farm. Inst., 12(2), pp. 97-101, 1978-Coden: Khfzan; ISSN: 0023-1134 (English Abstract).
Bergstrom Carl P.
Ding Min
Gentles Robert G.
He Feng
Hewawasam Piyasena
Bristol--Myers Squibb Company
Epperson James
Kosack Joseph R.
McKane Joseph K.
Mingo Pamela A.
LandOfFree
Inhibitors of HCV replication does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of HCV replication, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of HCV replication will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3719976